Abstract
PurposeTo investigate the safety and efficacy of CT-guided I125 radioactive seed implantation (RSI) as a salvage therapy for recurrent head and neck squamous carcinoma (rHNSC) after external beam radiotherapy (EBRT) or surgery.Materials and MethodsThis is a multicenter retrospective study of 113 patients (83 males; median age 57 years) with rHNSC who underwent CT-guided I125 RSI between February 2003 and December 2017. Of the included patients, 107 patients previously received EBRT and 65 patients received surgery and all were ineligible or rejected for salvage surgery and/or repeat EBRT.ResultsDuring a median follow-up duration of 20 months (range, 3-152 months), 87 patients died. The 1-, 2-, 3-, and 5-year local control rate were 57.4%, 41.8%, 29.3%, and 15.2%, respectively. The median time to progression was 15 months [95% confidence interval (CI), 6.1-23.9 months]. The median overall survival (OS) was 20 months (95% CI, 12.4-27.6 months). The 1-, 2-, 3-, and 5-year OS rate were 63.6%, 44.6%, 29.9%, and 21.7%, respectively. Univariate and multivariate analyses revealed that KPS score and postoperative D90 were significantly associated with patients’ OS. The complications were mainly grade I/II skin and mucosal reactions: 18 cases (15.9%) of grade I/II and eight cases (7.0%) of grade III radiation dermatitis, and 14 cases (12.4%) of grade I/II and three cases (2.7%) grade III mucosal reactions. No grade IV or severer complications were found.ConclusionCT-guided I125 RSI may be safe as a salvage therapy for rHNSC after EBRT/surgery, yielding promising efficacy compared with historical data. KPS score and postoperative D90 may be significantly associated with OS.
Highlights
Head and neck squamous carcinoma (HNSC) is the sixth most common cancer and accounts for over 600,000 new cancer cases and 350,000 deaths worldwide each year [1, 2]
Univariate analysis showed that age, sex, previous surgery, radiotherapy, chemotherapy, and site of recurrence were not associated with local control (p = 0.311, 0.079, 0.582, 0.511, 0.697, and 0.738, respectively)
Univariate analysis showed that age, sex, previous surgery/radiotherapy/chemotherapy, and site of recurrence were not associated with overall survival (OS) (p = 0.422, 0.793, 0.994, 0.328, 0.614, and 0.708, respectively)
Summary
Head and neck squamous carcinoma (HNSC) is the sixth most common cancer and accounts for over 600,000 new cancer cases and 350,000 deaths worldwide each year [1, 2]. Despite the high local control rate of HNSC, recurrent HNSC (rHNSC) still occurs in 20%-35% of the patients after surgery/chemoradiotherapy [3]. Though long-term survival is becoming more common in HNSC, the outcome for rHNSC is still very poor [4]. Salvage therapy for recurrent disease may preferentially benefit this subset; treatment options are limited [3]. Salvage surgery leads to a substantial improvement in outcomes for rHNSC it only can be used in highly selected patients [5]. EBRT can only be considered in well-selected patients but at the high cost of toxicity [3, 7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
